Ruxolitinib for CALR-positive Myelofibrosis: A Case Report and Literature Review

Ruxolitinib for CALR-positive Myelofibrosis: A Case Report and Literature Review

Bibliographic Details
Main Authors:	GUO Huimei, HUA Luoming, XUE Hua, WANG Jing, ZHAO Songying, ZHANG Jiangbo
Format:	Article
Language:	zho
Published:	Magazine House of Cancer Research on Prevention and Treatment 2018-08-01
Series:	Zhongliu Fangzhi Yanjiu
Online Access:	http://html.rhhz.net/ZLFZYJ/html/8578.2018.17.1621.htm

Similar Items

Presence of triple positive driver mutations in JAK2, CALR and MPL in primary myelofibrosis: a case report and literature review
by: Long Zhao, et al.
Published: (2024-12-01)

Ruxolitinib as an emerging treatment in myelofibrosis
by: Emanuel RM, et al.
Published: (2013-03-01)

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
by: Manduzio P
Published: (2017-02-01)

Homozygous CALR Mutation in Primary Myelofibrosis and Its Effect on Disease Phenotype: A Case Report and Review of the Literature
by: Qurratulain Rizvi, et al.
Published: (2019-01-01)

Disseminated Histoplasmosis in a Patient with Myelofibrosis on Ruxolitinib: A Case Report and Review of the Literature on Ruxolitinib-Associated Invasive Fungal Infections
by: Chia-Yu Chiu, et al.
Published: (2024-03-01)

Pleomorphic circulating megakaryocytes in a case of CALR positive primary myelofibrosis in leukemic transformation
by: Habib Moshref Razavi
Published: (2021-11-01)

JAK inhibitors and myelofibrosis, Einstein and ruxolitinib
by: Claire Harrison
Published: (2015-04-01)

Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis
by: Paola Guglielmelli, et al.
Published: (2023-01-01)

Tuberculosis in Patients with Primary Myelofibrosis During Ruxolitinib Therapy: Case Series and Literature Review
by: Peng Y, et al.
Published: (2020-09-01)

Practical management of patients with myelofibrosis receiving ruxolitinib.
by: Harrison, C, et al.
Published: (2013)

Hemostasis in patients with primary myelofibrosis treated with ruxolitinib
by: O. G. Golovina, et al.
Published: (2024-11-01)

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis
by: Naval Daver, et al.
Published: (2015-08-01)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
by: Ostojic A, et al.
Published: (2012-03-01)

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis
by: Timothy Devos, et al.
Published: (2022-01-01)

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
by: Srdan Verstovsek, et al.
Published: (2023-07-01)

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib
by: Maheen Z. Abidi, et al.
Published: (2016-01-01)

Unusual cause of dyspnea in patient with Myelofibrosis: The Ruxolitinib lung
by: Antoine El Kik, et al.
Published: (2024-01-01)

Marked Hyperbilirubinemia Associated with Primary Myelofibrosis Responsive to Ruxolitinib
by: Sunny Sandhu, et al.
Published: (2022-01-01)

Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications
by: David M. Ross, et al.
Published: (2021-01-01)

The Gordian knot: ruxolitinib or transplants for high-risk myelofibrosis
by: Robert Peter Gale, et al.
Published: (2024-07-01)

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
by: Bewersdorf JP, et al.
Published: (2019-12-01)

Management of paroxysmal nocturnal hemoglobinuria in CALR mutated post‐essential thrombocythemia myelofibrosis: A case report
by: Mahija Cheekati, et al.
Published: (2024-04-01)

Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis
by: Lasse Kjær, et al.
Published: (2023-05-01)

Persistent Basophilia May Suggest an “Accelerated Phase” in the Evolution of CALR-Positive Primary Myelofibrosis Toward Acute Myeloid Leukemia
by: Jerome Dobrowolski, et al.
Published: (2019-09-01)

Decision analysis for transplant candidates with primary myelofibrosis in the ruxolitinib era
by: Yosuke Okada, et al.
Published: (2024-06-01)

P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME
by: F. Palandri, et al.
Published: (2022-06-01)

Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis
by: Anna Hirano, et al.
Published: (2017-01-01)

P991: IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB
by: P. Harrington, et al.
Published: (2022-06-01)

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis
by: Claire Harrison, et al.
Published: (2022-08-01)

A phase I trial of pevonedistat in combination with ruxolitinib for the treatment of myelofibrosis
by: Tim Kong, et al.
Published: (2024-03-01)

Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib
by: Vera Stoeva, et al.
Published: (2023-07-01)

Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation
by: Leona Dold, et al.
Published: (2021-09-01)

Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib
by: Arthur E. Frankel, et al.
Published: (2021-04-01)

Ruxolitinib Treatment During Myelofibrosis Leads to Cutaneous Mycobacterium marinum Infection: A Case Report
by: Chen X, et al.
Published: (2023-06-01)

A Rare Co-Occurrence of Triple Mutations in JAK2, CALR, and MPL in the Same Patient with Myelofibrosis
by: Sherine J. Thomas, et al.
Published: (2022-01-01)

Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain
by: María Teresa Gómez-Casares, et al.
Published: (2017-11-01)

The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies
by: Vikas Gupta, et al.
Published: (2016-12-01)

Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib
by: Ruben Mesa, et al.
Published: (2023-06-01)

P1044: REAL-WORLD RUXOLITINIB TREATMENT PATTERN IN MYELOFIBROSIS PATIENTS WITH THROMBOCYTOPENIA
by: J. Mei, et al.
Published: (2022-06-01)

PB2173: THE EFFECT OF RUXOLITINIB THERAPY ON HEMOSTATIC PARAMETERS IN PATIENTS WITH PRIMARY MYELOFIBROSIS
by: Natalia Korsakova, et al.
Published: (2023-08-01)